A clinical formulation indicated for Asthma and Breathing. Facilitates the slowing of progressive lung scarring while supporting overall respiratory capacity.
Indicated to address lung scarring progression to alleviate respiratory decline and support improved oxygen capacity in patients with chronic fibrosing lung conditions.
Mechanism of Action
Nintedanib blocks receptor tyrosine kinases that trigger the growth and activation of lung fibroblasts. By inhibiting these pathways, it slows the excessive scarring of lung tissue that makes breathing difficult.
Route of Administration
Oral
Onset Time
Variable; months for clinical change
Duration
12 hours
Contraindications
Severe liver impairment, Hypersensitivity to peanut or soya, Pregnancy
Information for Ofev is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
